LCM
RNAC icon

Laurion Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Laurion Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,333
Closed -$453K – 920
2021
Q1 		$453K Hold
3,333
– – ﹤0.01% 603
2020
Q4 		$303K Buy
+3,333
New +$289K ﹤0.01% 543
2016
Q4 		– Sell
-833
Closed -$356K – 1257
2016
Q3 		$356K Hold
833
– – ﹤0.01% 699
2016
Q2 		$350K Buy
+833
New +$350K 0.01% 625

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Laurion Capital Management's RNAC Position: Q2 2021 in Review

Laurion Capital Management sold out of Cartesian Therapeutics (RNAC) in Q2 2021, closing a stake of 3,333 shares — an estimated $453K sold.

Laurion Capital Management first reported a position in RNAC in Q2 2016 and held it in 4 quarters. The position peaked at $453K in Q1 2021. 101 funds tracked by Wall St. Rank hold RNAC as of Q2 2021.

  • Laurion Capital Management reported no remaining Cartesian Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Laurion Capital Management sold 3,333 Cartesian Therapeutics shares in Q2 2021, an estimated $453K.
  • Laurion Capital Management first reported a position in Cartesian Therapeutics in Q2 2016 and held it in 4 quarters.
  • Laurion Capital Management's Cartesian Therapeutics position peaked at $453K in Q1 2021.
  • 101 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2021.

Based on Laurion Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.